Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   53 Trials   53 Trials   3175 News 
72 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Alecensa (alectinib) / Roche
2020-001737-13: Standard dose alectinib versus Therapeutic Drug Monitoring guided alectinib dosing

Not yet recruiting
4
186
Europe
Alectinib, CH5424802, Capsule, hard, Alecenso
University Medical Center Groningen, University Medical Center Groningen
Non-small cell lung carcinoma with ALK fusion, Stage IV disease; palliative setting, Diseases [C] - Cancer [C04]
 
 
2022-003275-42: The influence of different DIets on ALECTinib exposure in lung cancer patients;the DIALECT study.

Ongoing
4
10
Europe
Semaglutide, Concentrate for solution for injection, Wegovy
Weight gain is a common side effect of alectinib therapy. Semaglutide could be used as medical anti-obesity drug to prevent alectinib-induced weight gain. Since semaglutide delays gastric emptying, alectinib absorption may be influenced with a possible change in AUC. To test if semaglutide can be administered safely along with alectinib, without serious drug-drug interactions, a pharmacokinetic interaction-study is needed., To test if anti-obesity drug semaglutide can be administered safely along with alectinib, without serious interactions between the two drugs., Diseases [C] - Cancer [C04]
 
 
ChiCTR2000031670: Phase IV clinical trial for alectinib as first-line treatment of advanced non-small cell lung cancer with positive ALK gene.

Not yet recruiting
4
60
 
Alectinib
Department of Oncology, Maoming People's Hospital, Guangdong Province, China; Maoming People's Hospital of Guangdong Province, China, No
Advanced non-small cell lung cancer with positive ALK gene.
 
 
ADAPT ALEC, NCT05525338: Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels

Recruiting
4
196
Europe
Alectinib
University Medical Center Groningen, Amsterdam University Medical Center, Erasmus Medical Center, Maastricht University Medical Center, Radboud University Medical Center, The Netherlands Cancer Institute, Leiden University Medical Center
Drug Monitoring, Carcinoma, Non-Small-Cell Lung, Lung Cancer, Anaplastic Lymphoma Kinase Gene Mutation, Anaplastic Lymphoma Kinase Gene Translocation
12/25
12/26
J-ALEX, jRCT2080222267: study

Checkmark J-ALEX trial for first-line ALK+ NSCLC at ASCO 2016
Jun 2016 - Jun 2016: J-ALEX trial for first-line ALK+ NSCLC at ASCO 2016
Completed
3
200
Japan
Alecensa (alectinib) - Roche, Xalkori (crizotinib) - Pfizer
Chugai Pharmaceutical Co., Ltd.
Non-small cell lung cancer
 
 
ALEX, NCT02075840 / 2013-004133-33: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants

Checkmark Data from ALEX trial in ALK+ NSCLC at ASCO 2020
May 2020 - May 2020: Data from ALEX trial in ALK+ NSCLC at ASCO 2020
Checkmark Approval in China for ALK-positive NSCLC
Aug 2018 - Aug 2018: Approval in China for ALK-positive NSCLC
Checkmark Approved for 1L treatment of ALK-positive lung cancer
More
Active, not recruiting
3
303
Europe, Canada, US, RoW
Alectinib, RO5424802, Crizotinib
Hoffmann-La Roche
Non-Small Cell Lung Cancer
02/17
09/26
ALESIA, NCT02838420: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Checkmark ALESIA study in NSCLC
Oct 2018 - Oct 2018: ALESIA study in NSCLC
Active, not recruiting
3
187
RoW
Alectinib, RO5424802, Crizotinib
Hoffmann-La Roche
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
05/18
03/26
ALINA, NCT03456076 / 2017-004331-37: A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Active, not recruiting
3
257
Europe, Japan, US, RoW
Alectnib, RO5424802, Cisplatin, Vinorelbine, Navelbine, Gemcitabine, Gitrabin, Pemetrexed, Alimta®, Carboplatin
Hoffmann-La Roche
Carcinoma, Non-Small-Cell Lung
06/23
11/26
ALTA-3, NCT03596866 / 2018-001957-29: A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Active, not recruiting
3
248
Europe, Canada, US, RoW
Brigatinib, Alunbrig, Alectinib, Alecensa
Takeda
ALK+ Advanced NSCLC
02/24
09/24
NCT03194893 / 2017-000207-24: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

Recruiting
3
200
Europe, US, RoW
Alectinib, Crizotinib
Hoffmann-La Roche
Neoplasms
06/26
06/26
IMbrella B, NCT03768063 / 2018-003352-20: A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Recruiting
3
1000
Europe, Canada, Japan, US, RoW
Atezolizumab, Tecentriq, Bevacizumab, Avastin, Alectinib, Alecensa, Cobimetinib, Cotellic, Vemurafenib, Zelboraf, FAP IL2V, simlukafusp alfa, Venetoclax, Venclexta, Enzalutamide, Xtandi, Pembrolizumab, Keytruda, Sunitinib, Sutent, Niraparib, Zejula, Cabozantinib, Cometriq, Pemetrexed, Paclitaxel, Emactuzumab, Rucaparib
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd, F. Hoffmann- La Roche Ltd
Cancer
07/28
07/28
NCT05170204 / 2021-004149-19: A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
121
Europe, Canada, Japan, US, RoW
Alectinib, Entrectinib, Durvalumab
Hoffmann-La Roche
Non-Small Cell Lung Cancer
06/29
04/35
BFAST, NCT03178552 / 2017-000076-28: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

Checkmark Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Sep 2021 - Sep 2021: Results from B-FAST study for unresectable, advanced or metastatic NSCLC at ESMO 2021
Hourglass Apr 2021 - Jun 2021 : First-patient-in for cohort F of P2/3 B-FAST trial for NSCLC
Recruiting
2/3
1000
Europe, Canada, Japan, US, RoW
Alectinib, RO5424802, Atezolizumab, RO5541267, Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Entrectinib, RO7102122, Cobimetinib, RO5514041, Vemurafenib, RO5185426, Bevacizumab, RO4876646, Divarasib, RO7435846; GDC-6036, Docetaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer
08/28
08/28
Drugs-SNPs, NCT05987956: Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms

Not yet recruiting
2/3
600
US
Alectinib - Usual, Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily, Alectinib - Study, Study ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, UnitedHealthcare
Non-small Cell Lung Cancer
11/25
12/25
DETERMINE, NCT05722886: (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol

Recruiting
2/3
825
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Entrectinib, Rozlytrek, Trastuzumab in combination with pertuzumab, Herceptin in combination with Perjeta, Vemurafenib in combination with cobimetinib, Zelboraf in combination with Cotellic
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy
10/29
10/29
DETERMINE, NCT05770037: Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers

Recruiting
2/3
30
Europe
Alectinib, Alecensa
Cancer Research UK, University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, Hoffmann-La Roche
Solid Tumor, Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Cancer, Anaplastic Large Cell Lymphoma, Lymphoma, Renal Cell Carcinoma, Neuroblastoma
10/29
10/29
NCCH1901, jRCTs031190104: Patient-requested medical treatment with recommended treatment based on genetic profiling

Recruiting
2
Japan
imatinib - Generic mfg., everolimus - Generic mfg., Tafinlar (dabrafenib) - Novartis, BeiGene, Mekinist (trametinib) - Novartis, BeiGene, Votrient (pazopanib) - Novartis, Tasigna (nilotinib) - Novartis, Inhibikase, Jakafi (ruxolitinib) - Incyte, Zykadia (ceritinib) - Novartis, Tabrecta (capmatinib) - Incyte, Novartis, Alecensa (alectinib) - Roche, Herceptin (trastuzumab) - Roche, Tecentriq (atezolizumab) - Roche, Opdivo (nivolumab) - BMS, Mektovi (binimetinib) - Ono Pharma, Pierre Fabre, Pfizer
National Cancer Center Hospital
Solid tumors
 
 
ACTRN12621000312842: Cancer Molecular Screening and Therapeutics (MoST) Program and ASPiRATION subprogram, Addendum 14 – substudy 32: Alectinib

Recruiting
2
16
 
University of Sydney, Office for Health and Medical Research, OMICO - Outsmarting Cancer Together
Cancer, ALK gene alterations, Non-small cell lung cancer
 
 
2019-002230-37: Study of lorlatinib in patients with Lung cancer characterized by a modification of a gene called ALK after after a first line treatment by brigatinib or alectinib

Not yet recruiting
2
112
Europe
lorlatinib, PF6463922, Film-coated tablet, Lorviqua
IFCT, PFIZER, IFCT
advanced ALK-positive non-small cell Lung cancer, advanced lung cancer characterized by a modification of a gene called ALK, Diseases [C] - Cancer [C04]
 
 
2019-001316-38: A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Et lægemiddelforsøg af en individualiseret behandlingsstrategi til patienter med undertypen non-clear celle nyrekræft, som har spredt sig

Not yet recruiting
2
30
Europe
Capsule, hard, Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Tafinlar, Tarceva, Keytruda, Mekinist, Alecensa, Lynparza, Kadcyla, Cabometyx, Xalkori, Ibrance, Tagrisso, Glivec, Sutent, Opdivo
Department of Oncology, Herlev University Hospital, Region Hovedstaden, Roche Denmark
Patients with metastatic non-clear cell or 100% sarcomatoid renal cell carcinoma referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med metastatisk non-clear cell eller 100% sarkomatoid nyrekræft, som henvises med henblik på første linje behandling på onkologisk afdeling, Herlev Hospital, Patients with metastatic kidney cancer with the subtype non-clear cell or 100% sarcomatoid referred for first line treatment at the Department of Oncology, Herlev University Hospital Patienter med undertypen non-clear cell eller 100% sarkomatoid nyrekræft, som har spredt sig og henvises for at påbegynde den første medicinske kræftbehandling på onkologisk afdeling, Herlev Hospital, Diseases [C] - Cancer [C04]
 
 
2019-001828-36: Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Not yet recruiting
2
116
Europe
Brigatinib, Alecensa, Zykadia, Film-coated tablet, Capsule, hard, Alunbrig
Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Takeda Pharmaceutical Company Ltd
Anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC), Non-small cell lung cancer, Diseases [C] - Cancer [C04]
 
 
ALTA-2, NCT03535740: A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Active, not recruiting
2
103
Europe, Canada, Japan, US, RoW
Brigatinib, AP26113
Ariad Pharmaceuticals, Takeda
ALK-positive Advanced NSCLC
09/20
08/24
2020-003395-41: Ex vivo drug sensitivity in metastatic colorectal cancer

Not yet recruiting
2
45
Europe
Alectinib, Crizotinib, Dasatinib, Everolimus, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Pertuzumab, Trastuzumab, Talazoparib, Venetoclax, Cetuximab, Encorafinib, Capsule, hard, Film-coated tablet, Tablet, Infusion, Injection, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Alecensa, Xalkori, Sprycel, Afinitor, Gemcitabine Accord, Zydelig, Vitrakvi, Methotrexat Accord, Ibrance, Farydak, Keytruda, Perjeta, Herceptin, Talzenna, Venclyxto, Erbitux, Braftovi
Oslo University Hospital, Oslo University Hospital
Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Diseases [C] - Cancer [C04]
 
 
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
2019-003192-18: Phase II clinical trial with early efficacy testing and adaptive extension for rare malignant tumors

Not yet recruiting
2
175
Europe
Alectinib, Tecentriq, Vemurafenib, Cobimetinib, Ipatasertib, Herceptin, Perjeta, Inavolisib, 7113755, Capsule, hard, Infusion, Film-coated tablet, Powder for infusion, Concentrate for solution for infusion, Tecentriq, Herceptin, Perjeta
German Cancer Research Center, German Cancer Research Center, Roche Pharma AG
Metastatic or locally advanced malignancies, Previously Treated Advanced tumours, Diseases [C] - Cancer [C04]
 
 
NRG-LU003, NCT03737994: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Active, not recruiting
2
10
US
Alectinib, AF 802, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH 5424802, CH-5424802, CH5424802, RG 7853, RG-7853, RG7853, RO 5424802, RO-5424802, RO5424802, Brigatinib, Alunbrig, AP 26113, AP-26113, AP26113, Biganib, Briganix, Trepmac, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ceritinib, LDK 378, LDK-378, LDK378, Zykadia, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF 02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Ensartinib, Ensacove, X 396, X-396, X396, Lorlatinib, 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-, Lorbrena, Lorviqua, PF 06463922, PF-06463922, PF06463922, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy
National Cancer Institute (NCI), NRG Oncology
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
07/21
09/24
2021-000689-14: Finnish national phase 2 study to evaluate targeted drug treatment in advanced cancer. Yksilöllistä syövänhoitoa selvittävä kansallinen vaiheen 2 lääketutkimus edenneessä syövässä.

Not yet recruiting
2
250
Europe
abemaciclib, pralsetinib, Tablet, Capsule, hard, Injection, Infusion, Capsule, Stivarga, Alecensa, Cotellic, Erivedge, Phesgo, Rozlytrek, Tecentriq, Zelboraf, Verzenios, Retsevmo, Erleada, Tafinlar, Mekinist, Gavreto, Lynparza
Helsinki University Hospital, Helsinki University Hospital
Patients with an advanced solid tumor for which standard treatment options no longer exist and with acceptable performance status and organ function with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test., Patients with advanced cancer where standard treatment options no longer exist. Potilaat, jotka sairastava edennyttä syöpää, johon tavanomaiset hoitolinjat eivät enää tehoa., Diseases [C] - Cancer [C04]
 
 
2021-002352-36: A Study to Evaluate the Efficacy and Safety of Alectinib in Locally Advanced or Metastatic ALK-Positive Solid Tumors

Not yet recruiting
2
50
Europe
Alectinib, RO5424802, Capsule, hard, Alecensa
F. Hoffmann La Roche Ltd., F.Hoffmann-La Roche, Ltd.
Anaplastic lymphoma kinase (ALK)-positive solid tumors, Solid tumors are masses of abnormal tissue growth that originate in organs or soft tissues and do not include fluid areas and cysts, Diseases [C] - Cancer [C04]
 
 
NCT04423185: PLATFORM Study of Precision Medicine for Rare Tumors

Not yet recruiting
2
770
NA
Almonertinib 110 MG, HS-10296, AMEILE, Dacomitinib 45 MG, Vizimpro, Alectinib 150 MG, Alecensa, Crizotinib 250 MG, Xalkori, Pyrotinib 160/80 MG, SHR-1258, Imatinib 400 MG, Gleevec, Niraparib 200/300 MG, Niraparix, Palbociclib 125mg, Ibrance, Vemurafenib 240 MG, Zelboraf, Sintilimab 100MG, Tyvyt, Atezolizumab 1680 MG, TECENTRIQ
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Rare Tumor
07/22
07/23
NCT03779191: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Completed
2
41
RoW
Alectinib, Alecensa, Bevacizumab, Avastin
Instituto Nacional de Cancerologia de Mexico, Roche Pharma AG
ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung
08/22
10/22
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

Recruiting
2
6000
RoW
Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc.
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation
12/26
12/27
CUPISCO, NCT03498521 / 2017-003040-20: A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site

Active, not recruiting
2
528
Europe, Japan, RoW
Alectinib, Vismodegib, Ipatasertib, Olaparib, Erlotinib, Bevacizumab, Vemurafenib, Cobimetinib, Trastuzumab Subcutaneous (SC), Pertuzumab, Atezolizumab, Carboplatin, Paclitaxel, Cisplatin, Gemcitabine, Entrectinib, Ivosidenib, Pemigatinib
Hoffmann-La Roche, Foundation Medicine, Inc.
Cancer of Unknown Primary Site
02/23
06/24
NCT02091141: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Checkmark ASCO 2016
Jun 2016 - Jun 2016: ASCO 2016
Checkmark ASCO-GI 2016
Jan 2016 - Jan 2016: ASCO-GI 2016
Completed
2
673
US
Trastuzumab, Herceptin, Pertuzumab, Perjeta, Erlotinib, Tarceva, Vemurafenib, Zelboraf, Cobimetinib, Cotellic, Vismodegib, Erivedge, Alectinib, Alecensa, Atezolizumab, Tecentriq
Genentech, Inc.
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
05/23
05/23
ALNEO, NCT05015010 / 2020-003432-25: Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Active, not recruiting
2
33
Europe
Alectinib
Gruppo Oncologico Italiano di Ricerca Clinica
Non Small Cell Lung Cancer
12/24
12/26
BLISS, NCT05081674: Brazilian Lung Immunotherapy Study

Completed
2
154
RoW
Alectinib, Alecensa, Pembrolizumab, Keytruda, Nivolumab, Opdivo, Erlotinib, Tarceva
Hospital Israelita Albert Einstein, Ministry of Health, Brazil
Lung Neoplasm
06/23
07/23
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

Recruiting
2
78
RoW
Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN
Hunan Province Tumor Hospital
ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy
11/26
02/27
MyTACTIC, NCT04632992: A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed
2
252
US
Entrectinib, Rozlytrek™, RG6268, RO7102122, Inavolisib, GDC-0077, RG6114, RO7113755, Alectinib, Alecensa®, RG7853, RO5424802, Ipatasertib, GDC-0068, RG7440, RO5532961, Atezolizumab, Tecentriq®, RG7446, RO5541267, Trastuzumab Emtansine, Kadcyla®, RG3502, RO5304020, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, PHESGO™, PH FDC SC, Fixed dose combination of trastuzumab and pertuzumab administered subcutaneously, RG6264, RO7198574, Tucatinib, Tukysa™, Investigator's Choice of Chemotherapy, Paclitaxel, Tiragolumab, RG6058, RO7092284, MTIG7192A, Pralsetinib, GAVRETO™, RG6396, RO7499790
Genentech, Inc.
Advanced Unresectable or Metastatic Solid Malignancy
12/23
02/24
ChiCTR2000039310: Platform Study of Genotyping Guided Precision Medicine for Rare Tumors in China

Recruiting
2
208
 
Almonertinib, 110mg, qd ;Dacomitinib, 450mg, qd ;Alectinib, 600mg, bid ;Crizotinib, 250mg, bid ;Zelboraf, 960mg, bid ;Niraparib,200-300mg,qd ;Pyrotinib, 400mg, qd ;Imatinib, 400mg, bid ;Palbociclib, 125mg,*21d, q28d ;Sintilimab, 200mg, q21d ;Atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d ;atezolizumab, 1200mg, q21d
National Cancer Center/National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Cancer Hospital of Chinese Academy of Medical Sciences, self-raised
Rare Tumors
 
 
NAUTIKA1, NCT04302025: A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

Recruiting
2
125
US
Alectinib, Entrectinib, Vemurafenib (Enrollment closed), Cobimetinib (Enrollment closed), Pralsetinib (Enrollment closed), Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Genentech, Inc., Blueprint Medicines Corporation
Non-small Cell Lung Cancer
12/25
03/29
ProTarget, NCT04341181: - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling

Recruiting
2
300
Europe
Alectinib, Alecensa, Atezolizumab, Tecentriq, Avelumab, Bavencio, Axitinib, Inlyta, Erlotinib, Tarceva, Vemurafenib plus Cobimetinib (combination), Zelboraf plus Cotellic (combination), Trastuzumab plus Pertuzumab (combination), Herceptin plus Perjeta (combination), Trastuzumab emtansine, Kadcyla, Vismodegib, Erivedge, Niraparib, Zejula
Ulrik Lassen, Roche Pharma AG, Pfizer, GlaxoSmithKline
Cancer, Tumors, Neoplasms, Neoplasia
04/24
04/25
DARWIN II, NCT02314481: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity

Active, not recruiting
2
50
Europe
MPDL3280A, Atezolizumab, Vemurafenib, Zelboraf, Alectinib, Alecensa, Trastuzumab emtansine, T-DM1, Kadcyla
University College, London, Hoffmann-La Roche
Non-small Cell Lung Cancer
05/26
05/26
ROME, NCT04591431 / 2018-002190-21: The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

Active, not recruiting
2
400
Europe
Erlotinib, Trastuzumab, Trastuzumab emtansine, Pertuzumab, Lapatinib, Everolimus, Vemurafenib, Cobimetinib, Alectinib, Brigatinib, Palbociclib, Ponatinib, Vismogedib, Itacitinib, Ipatasertib, Entrectinib, Atezolizumab, Nivolumab, Ipilimumab, Pemigatinib, Oncology Drugs, Pralsetinib, Selpercatinib, Talazoparib, Tepotinib, Alpelisib
Fondazione per la Medicina Personalizzata
Breast Cancer, Gastrointestinal Cancer, Non Small Cell Lung Cancer, Other Cancer
12/24
06/25
NCT05296278: Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Recruiting
2
70
RoW
IBI-323 combined with bevacizumab plus Platinum
Hunan Province Tumor Hospital
Non Small Cell Lung Cancer
12/25
04/26
CRAFT, NCT04551521: The NCT-PMO-1602 Phase II Trial

Recruiting
2
175
Europe
Vemurafenib, Cobimetinib, Atezolizumab, Trastuzumab, Pertuzumab, Alectinib, Ipatasertib, Inavolisib
German Cancer Research Center
Metastatic or Locally Advanced Malignancies
06/25
06/25
ORCHARD, NCT03944772 / 2018-003974-29: Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy

Hourglass Jan 2022 - Dec 2023 : Data from ORCHARD trial for advanced EGFRm NSCLC
Active, not recruiting
2
248
Europe, Japan, US, RoW
Osimertinib, TAGRISSO, Savolitinib, Gefitinib, Iressa, Necitumumab, Portrazza, Durvalumab, IMFINZI, Carboplatin, Pemetrexed, Alectinib, Alecensa, Selpercatinib, Loxo-292, Retevmo, Retsevmo, Selumetinib, Koselugo, Etoposide, Cisplatin, Datopotamab deruxtecan, DS 1062a
AstraZeneca
Non-Small Cell Lung Cancer
05/25
05/25
ChiCTR2300070038: Efficacy of alectinib combined with carbamazepine in the treatment of symptomatic epilepsy in patients with EGFR mutant lung cancer with meningeal metastases by intrathecal injection of pemetrexed

Not yet recruiting
2
15
 
ntrathecal carbamazepine, ametinib, and pemetrexed
The Second Affiliated Hospital of Harbin Medical University; The Second Affiliated Hospital of Harbin Medical University, Beijing Xisike Clinical Oncology Research Foundation
Symptomatic epilepsy in meningeal metastases from lung cancer
 
 
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Recruiting
2
455
Europe
HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib
Centre Leon Berard
Malignant Solid Tumor
02/26
11/26
FINPROVE, NCT05159245: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Tepotinib, Tepmetko, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pemigatinib, Pemazyre
Helsinki University Central Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
TAPISTRY, NCT04589845 / 2020-001847-16: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You () Platform Study

Recruiting
2
920
Europe, Canada, Japan, US, RoW
Entrectinib, Rozlytrek, Alectinib, Alecensa, Atezolizumab, Tecentriq, Ipatasertib, Trastuzumab emtansine, Kadcyla, Idasanutlin, Inavolisib, GDC-0077, Belvarafenib, Pralsetinib, Gavreto (US), GDC-6036, Camonsertib
Hoffmann-La Roche
Solid Tumors
09/32
09/32
EVIDENT, NCT05725200: Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting
2
40
Europe
Alectinib, Cetuximab, Crizotinib, Dasatinib, Everolimus, Encorafenib, Gemcitabine, Idelalisib, Larotrectinib, Methotrexate, Palbociclib, Panobinostat, Pembrolizumab, Petrozumab, Trastuzumab, Talazoparib, Venetoclax
Oslo University Hospital
Metastatic Colorectal Cancer
12/38
12/40
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
NCT01588028: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer

Checkmark In pts with crizotinib-resistant ALK-rearranged NSCLC
Aug 2014 - Aug 2014: In pts with crizotinib-resistant ALK-rearranged NSCLC
Checkmark WCLC 2013
Oct 2013 - Oct 2013: WCLC 2013
Checkmark ESMO-ECCO-ESTRO 2013
More
Active, not recruiting
1/2
36
US
CH5424802
Hoffmann-La Roche
ALK-Rearranged Non-Small Cell Lung Cancer
09/15
09/15
NCT03202940: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

Active, not recruiting
1/2
16
US
Alectinib, Alecensa, Cobimetinib, Cotellic
Massachusetts General Hospital, Genentech, Inc.
Non-small Cell Lung Cancer
01/25
01/27
NOA-20, NCT03158389 / 2015-002752-27: NCT Neuro Master Match - N²M²

Completed
1/2
228
Europe
APG101, Alectinib, Alecensa, Idasanutlin, Atezolizumab, Vismodegib, Erivedge, Temsirolimus, Troisel, Palbociclib, Ibrance
University Hospital Heidelberg, German Cancer Aid, German Cancer Research Center, National Center for Tumor Diseases, Heidelberg
Glioblastoma, Adult
02/23
02/23
NCT05713006: Alectinib Pharmacokinetic in Patients With NSCLC

Recruiting
1/2
45
RoW
Alectinib Oral Product, Alecensa 150 mg Roche
Instituto Nacional de Cancerologia de Mexico
Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation
12/24
12/25
DURABLE, NCT05987644: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Recruiting
1/2
56
US
Alectinib, Stereotactic Radiosurgery, SRS
Joshua Palmer, Genentech, Inc.
Lung Cancer, NSCLC, Brain Metastases
01/26
01/27
GO42286, NCT04774718 / 2020-004239-25: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Recruiting
1/2
42
Europe, Canada, US, RoW
Alectinib
Hoffmann-La Roche
ALK Fusion-positive Solid or CNS Tumors
06/26
07/30
CMUH110-REC3-246, NCT06354387: Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Recruiting
1
8
RoW
Alectinib (Alecensa), Nivolumab (Opdivo), Alectinib (Alecensa)+ Nivolumab (Opdivo)
China Medical University Hospital
Hepatocellular Carcinoma
12/24
06/25
ACT, NCT05238831: SMMART Adaptive Clinical Treatment () Trial

Withdrawn
1
25
NA
Alectinib, AF-802, AF802, Alecensa, ALK Inhibitor RO5424802, CH5424802, RG7853, RO5424802, Alpelisib, BYL719, Phosphoinositide 3-kinase Inhibitor BYL719, Piqray, VIJOICE, Anastrozole, Anastrazole, Arimidex, ICI D1033, ICI-D1033, ZD-1033, Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Zirabev, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cobimetinib, Cotellic, GDC-0973, MEK Inhibitor GDC-0973, XL518, Entrectinib, Rozlytrek, RXDX 101, RXDX-101, RXDX101, Eribulin, ER-086526, Fulvestrant, Faslodex, Faslodex(ICI 182,780), ICI 182,780, ICI 182780, ZD9238, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo, Irinotecan, Letrozole, CGS 20267, Femara, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, Protein-bound Paclitaxel, Niraparib, MK-4827, MK4827, Olaparib, AZD 2281, AZD-2281, AZD2281, KU-0059436, Lynparza, PARP Inhibitor AZD2281, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Palbociclib, 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-8h-pyrido(2,3-d)pyrimidin-7-one, Ibrance, PD 0332991, PD 332991, PD 991, PD-0332991, Pertuzumab, 2C4, 2C4 Antibody, EG1206A, HLX11, HS627, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, Pertuzumab Biosimilar EG1206A, Pertuzumab Biosimilar HLX11, Pertuzumab Biosimilar HS627, rhuMAb2C4, RO4368451, Quality-of-Life Assessment, Quality of Life Assessment, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, QL 1701, QL-1701, QL1701, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar QL1701, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate, Vemurafenib, BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Zelboraf, Vinorelbine, Dihydroxydeoxynorvinkaleukoblastine, Vismodegib, Erivedge, GDC-0449, Hedgehog Antagonist GDC-0449
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
05/26
05/26
NCT02271139: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

No Longer Available
N/A
US
Alectinib
Genentech, Inc.
Non-Small Cell Lung Cancer
 
 
TOSS-ALK, NCT06339554: Alectinib-induced Endocrine Toxicity

Completed
N/A
98
Europe
Alectinib 150 MG [Alecensa], Alecensa
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV
10/23
10/23
GALILEO, NCT06234579: Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Recruiting
N/A
108
Europe
Biopsy (tissue or liquid), Alectinib, Brigatinib, Lorlatinib
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
ALK Gene Mutation, NSCLC Stage IV, ALK Sensitizing Mutation
03/26
07/26
MonAlec, NCT04708639: Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

Enrolling by invitation
N/A
40
Europe
Alectinib
Aarhus University Hospital, Roche Pharma AG
Lung Cancer, ALK Gene Mutation, Resistance, Disease, Mutation
06/22
06/25
NCT04351334: Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Completed
N/A
1
US
Alectinib
Pfizer
Non-Small-Cell Lung Carcinoma
11/22
11/22
NCT03546894: A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed
N/A
111
US
Brigatinib, Alectinib, Ceritinib, Lorlatinib, Any FDA Approved ALK Inhibitors
Takeda
Anaplastic Lymphoma Kinase-positive, Carcinoma Non-small-cell Lung
02/23
02/23
NCT05710133: The Food-effect on Alectinib Pharmacokinetics

Active, not recruiting
N/A
10
Europe
food, food state, fast, fast state
The Netherlands Cancer Institute
NSCLC
03/25
03/25
A-SAB, NCT05724004: Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement

Recruiting
N/A
70
Europe
SBRT/SRS/radiation therapy
Karolinska University Hospital, Sahlgrenska University Hospital, Sweden
Radiotherapy Side Effect, Non-small Cell Lung Cancer, ALK Gene Mutation
06/24
06/31
EROS, NCT06532149: ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Recruiting
N/A
80
Europe
Alectinib, Alecensa, Brigatinib, ALUNBRIG, Lorlatinib 100 mg, LORVIQUA, Osimertinib, Sotorasib, Dabrafenib, Trametinib, Selpercatinib, Pembrolizumab, Cemiplimab, Nivolumab, Carboplatin, Pemetrexed, Paclitaxel
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NSCLC Stage IV, Sex Disorder, Hypogonadism, Male, Erectile Dysfunction
09/26
09/26
DELINOR, NCT05834348: A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Completed
N/A
1
Europe
lorlatinib, crizotinib, brigatinib, ceritinib, alectinib, atezolizumab, bevacizumab, paclitaxel, carboplatin, docetaxel, erlotinib, gefitinib, afatinib, dacomitinib, osimertinib, pembrolizumab, nivolumab, entrectinib
Pfizer
Non-Small Cell Lung Cancer
01/24
01/24
KOSMOS-II, NCT05525858: KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

Recruiting
N/A
1000
RoW
Alectinib, Alecensa, Atezolizumab, Tecentriq, Erlotinib, Tarceva, Trastuzumab + Pertuzumab, Herceptin + Perjeta, Trastuzumab emtansine, Kadcyla, Vemurafenib, Zelboraf, Bevacizumab + Erlotinib, Avastin + Tarceva, Entrectinib, Rozlytrek, Pralsetinib, Gavreto
Seoul National University Bundang Hospital, Korean Cancer Study Group, Roche Pharma AG
Solid Tumor, Advanced Solid Tumor, Metastatic Cancer
09/26
03/27
ReAlec, NCT04764188: An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

Active, not recruiting
N/A
800
Europe, RoW
Alectinib
Hoffmann-La Roche
NSCLC
05/27
05/27

Download Options